Die „Münsteraner Klassifikation“

Schmidt, Catarina; Bartholomäus, E; Deuster, Dirk; Heinecke, A.; Dinnesen, A. G.

doi:10.1007/s00106-005-1368-1

Cited by 52 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the NCI-CTCAE scale [6], the Brock [8] and the SIOP Boston [1] ototoxicity scales, which were primarily developed as outcome measures to report the incidence and severity of acquired hearing loss in children after completion of platinum-based chemotherapies, the Muenster classification was optimized for the early detection of ototoxicity during cisplatin treatment. Considering tinnitus and minimal hearing loss (>10 to ≤20 dB HL) as grade 1 the Muenster classification consequently identified more patients with hearing impairment than the NCI-CTCAE scale and the Brock scale [1, 8, 11]. Despite of using the more sensitive Muenster classification for phenotyping of the pediatric cohort, we were also able to confirm significant findings for rs316019 in the adult cohort graded for ototoxicity according to the less sensitive NCI-CTCAE criteria.…”

Section: Discussionmentioning

confidence: 62%

“…Finally, 49 patients had to be excluded from the final comparison because of nonevaluable audiograms, missing baseline audiograms or missing audiograms after completion of therapy (Figure 1). Based on the results of their audiological examination the remaining 64 patients were classified into group N (no ototoxicity) and O (ototoxicity) according to the Muenster classification [11]. Group O comprised 36 patients who experienced hearing impairment ≥1 during cisplatin treatment and group N consisted of 28 patients with no signs of ototoxicity (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…If necessary, brainstem audiometry was performed. The degree of hearing impairment was determined by using the ‘Muenster classification’ for early detection of cisplatin-induced bilateral high-frequency hearing loss [11]. A pure tone audiogram of grade 0 was necessary to enter the study.…”

Section: Methodsmentioning

confidence: 99%

“…Both grading systems considered 20 dB HL besides 40 dB HL as hearing loss in order to detect mild hearing losses. The Muenster classification, which was applied in this study, further considers tinnitus and minimal hearing losses (>10 to ≤20 dB HL) to already catch beginning ototoxicity classified as grade 1 [8, 10, 11]. Compared to existing scales the acquisition of changes as low as >10 to ≤20 dB HL after the second cisplatin dose by the Muenster classification identifies patients at risk for serious hearing impairment with high sensitivity and predictivity [12].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Human OCT2 Variant C.808G>T Confers Protection Effect Against Cisplatin-Induced Ototoxicity

et al. 2015

View full text Add to dashboard Cite

Aim Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients’ susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. Patients & methods Genotyping was performed in 64 pediatric patients and significant findings were re-evaluated in 66 adults. Results The SLC22A2 polymorphism rs316019 (c.808G>T; Ser270Ala) was significantly associated with protection from cisplatin-induced ototoxicity in the pediatric (p = 0.022) and the adult cohort (p = 0.048; both: Fisher’s exact test). This result was confirmed by multiple logistic regression analysis accounting for age which was identified as a relevant factor for ototoxicity as well (rs316019: OR [G/T vs G/G] = 0.12, p = 0.009; age: OR [per year]: 0.84, p = 0.02). Conclusion These results identified rs316019 as potential pharmacogenomic marker for cisplatin-induced ototoxicity and point to a critical role of SLC22A2 for cisplatin transport in humans and its contribution to the organ specific side effects of this drug.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Human OCT2 Variant C.808G>T Confers Protection Effect Against Cisplatin-Induced Ototoxicity

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Currently there is no universally acceptable classification of clinical manifestation of ototoxicity. Therefore, hearing loss representing ototoxicity was determined by adapting and simplifying "Muenster's classification", where worsening by ≥ 10 dB in ≥2 examined frequencies or ≥ 15 dB in 1 examined frequency (as recorded by hfPTA examination) was considered as a manifestation of ototoxicity [25].…”

Section: Methodsmentioning

confidence: 99%

Genetic risk factors of cisplatin induced ototoxicity in adult patients

Talach¹,

Rottenberg²,

Gál³

et al. 2016

neo

View full text Add to dashboard Cite

Ototoxicity is an important adverse effect of using Cisplatin (cis-diamminedichloroplatinum) (CDDP) as a form of chemotherapy. The clinical picture of CDDP induced ototoxicity includes perceptive hearing impairment (reversible or permanent) and tinnitus. Ototoxicity manifests with considerable variability between patients. The objective of this prospective study was to investigate a possible genetic background to this variability. We assessed ototoxicity induced by therapeutic doses of CDDP in adult patients with germinative testicular tumors, or other tumors treated with an identical CDDP dosage scheme. Audiological examination before, during and after the treatment has shown deterioration in hearing; first in the high-frequencies and with increased CDDP cumulative doses, impairment in other frequencies as well. Occurrence of tinnitus was not dependent on the administered dose of CDDP, or the other risk factors examined in this study. The association of CDDP induced ototoxicity with genetic polymorphisms in candidate genes was examined. Our study has demonstrated an association of early onset of CDDP induced ototoxicity with the presence of two copies of GSTT1 gene (p=0,009) and with T allele of rs9332377 polymorphism in COMT gene (p=0,001).

show abstract

Hearing loss and history of otolaryngological conditions in adults with microdeletion 22q11.2

von Scheibler,

Widdershoven,

van Barneveld

et al. 2023

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Previous studies have shown that the 22q11.2 microdeletion, associated with 22q11.2 deletion syndrome (22q11.2DS), conveys an increased risk of chronic otitis media, and hearing loss at young age. This study reports on hearing loss and history of otolaryngological conditions in adults with 22q11.2DS. We conducted a retrospective study of 60 adults with 22q11.2DS (41.7% male) at median age 25 (range 16–74) years who had visited an otolaryngologist and audiologist for routine assessment at a 22q11.2 expert center. Demographic, genetic, audiometric, and otolaryngological data were systematically extracted from the medical files. Regression analysis was used to evaluate the effect of age, sex, full‐scale intelligence quotient, and history of chronic otitis media on the severity of hearing loss. Hearing loss, mostly high‐frequency sensorineural, was found in 78.3% of adults. Higher age and history of chronic otitis media were associated with more severe hearing loss. Otolaryngological conditions with possible treatment implications included chronic otitis media (56.7%), globus pharyngeus (18.3%), balance problems (16.7%), and obstructive sleep apnea (8.3%). The results suggest that in 22q11.2DS, high‐frequency hearing loss appears to be common from a young adult age, and often unrecognized. Therefore, we recommend periodic audiometric screening in all adults, including high‐frequency ranges.

show abstract

Die „Münsteraner Klassifikation“

Abstract: The Muenster classification is a suitable new basis for scientific questions concerning cisplatin ototoxicity. It detects hearing loss earlier and maps progression of hearing loss more precisely than the existing high frequency classifications (Khan et al. and Brock et al.).

Cited by 52 publications

References 17 publications

Human OCT2 Variant C.808G>T Confers Protection Effect Against Cisplatin-Induced Ototoxicity

Human OCT2 Variant C.808G>T Confers Protection Effect Against Cisplatin-Induced Ototoxicity

Genetic risk factors of cisplatin induced ototoxicity in adult patients

Hearing loss and history of otolaryngological conditions in adults with microdeletion 22q11.2

Contact Info

Product

Resources

About